RxDoctor Payments Data

Brian Rajca, MD

Internal Medicine · Cape Coral, FLNPI 1083876197

Payments from drug & device makers

$2,714in general payments, 2019–2025

Across 117 payments — averaging $23.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Sanofi$226
  • Axonics, Inc.$161
  • Takeda Pharmaceuticals U.S.A., Inc.$146
  • Johnson & Johnson$138
  • Phathom Pharmaceuticals, Inc.$130
  • plus $737 from 14 others

What the payments were for

  • Food & beverage$2,68199%
  • Education$331%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,714 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$312,545
Medicare patients
1,041
Services billed
2,048

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase50$203,742
Humira(Cf) PenAdalimumab13$104,371
Humira PenAdalimumab14$94,812
ZenpepLipase/Protease/Amylase17$77,618
LinzessLinaclotide85$72,569
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates163$11,059
Mesalamine34$9,217
TrulancePlecanatide14$9,053
Pantoprazole Sodium496$5,106
Colestipol Hcl92$4,300
Famotidine326$4,181
Omeprazole327$3,499
Esomeprazole Magnesium87$3,276
Lubiprostone18$3,033
Mesalamine DrMesalamine12$2,939

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,175$276,311135 claims
Aimmune Therapeutics, Inc.Zenpep$13$77,61817 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$87$9,05314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Cape Coral

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →